Cardiac tumors secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention. | Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention. | ||
The concept of secondary prevention is useful during the treatment of cardiac tumors with chemotherapy. | The concept of secondary prevention is useful during the treatment of cardiac tumors with chemotherapy. | ||
**Most pharmaceutical approaches for long-term tumor survivors exposed to cardiotoxic medications have been adopted from investigations of adults. | |||
**To avoid the development of silent LVSD to clinical disease, these measures include proactive screening and administration of '''angiotensin-converting enzyme (ACE) inhibitors and Beta-blockers.''' | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 14:03, 14 June 2022
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors secondary prevention |
|
Risk calculators and risk factors for Cardiac tumors secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Template:Dj
Overview
Secondary Prevention
Definition: Secondary prevention focuses on early illness identification and targets persons who appear healthy but have subclinical disease types. The subclinical disease is characterized by pathologic alterations, but lacks overt manifestations that can be diagnosed during a doctor's visit.
Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention. The concept of secondary prevention is useful during the treatment of cardiac tumors with chemotherapy.
- Most pharmaceutical approaches for long-term tumor survivors exposed to cardiotoxic medications have been adopted from investigations of adults.
- To avoid the development of silent LVSD to clinical disease, these measures include proactive screening and administration of angiotensin-converting enzyme (ACE) inhibitors and Beta-blockers.